RNTX Rein Therapeutics Inc.
Healthcare$1.07+3.88%ClosedMarket Cap: $29.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.70
P/S
0.00
EV/EBITDA
-1.36
DCF Value
$-0.01
FCF Yield
-57.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-258.4%
ROA
-191.0%
ROIC
-120.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-5.2M | $-5.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.0M | $-32.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-21.9M | $-49.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.5M | $-5.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.9M | $-6.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.6M | $-5.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.8M | $-41.0M | $— | — |
| FY null | $0.00 | NaN% | $-65.1M | $-62.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-6.1M | $-5.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-9.0K | $-8.9K | $— | — |
| Q1 null | $0.00 | NaN% | $-7.2K | $-7.1K | $— | — |
| Q4 2023 | $0.00 | NaN% | $-7.3K | $-7.3K | $-1.54 | — |